Keywords: Anticoagulants, thromboembolism, Xarelto, Bayer, apixaba, Bristol-Myes, Pradaxa, Boehringer Ingelheim

Novel oral anticoagulants will drive venous thromboembolism market to nearly double by 2018

Article | 01 April 2010

Print This

The launches and widespread uptake of novel oral anticoagulants will drive the venous thromboembolism drug market to nearly double from $2.9 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in